Skip to main content

Table 4 HPV prevalence in males participating in circumcision clinical trials

From: Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review

Author Area, subjects Study design HPV test HPV prevalence for HR*, and LR** genotypes at enrollment and 24 month follow up in intervention§ and control§§ HPV prevalence for any, HR* and LR** genotypes at baseline and 24-month follow-up Risk Ratio (RR) and 95% CI† for any, HR*, LR** and multiple HPV infections at baseline and 24-month follow-up
Tobian et al., 2009 [58] Rakai district, 307 men in intervention and 233 men in control group aged 15-49 years who had detectable beta-globulin or HPV. Preputal cavity sampled Randomized controlled trial Roche HPV linear array. HR-HPV genotypes 16, 18,31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 tested At enrollment
HR-HPV genotypes a
Intervention group, 38.1%
Control group, 37.1%
At 24 months
HR-HPV genotypes a
Intervention group, 18.0%
Control group, 27.9%
Intervention
Any HPV genotypeb
Baseline, 61.9%
At 24 months, 35.6%
HR-HPV genotypes b
Baseline, 38.1%
At 24 months, 18.0%
LR-HPV genotypes b
Baseline, 47.6%
At 24 months, 26.2%
Control group
Any HPV typesb
Baseline, 62.6%
At 24 months, 51.2%
HR-HPV genotypes b
Baseline, 37.1%
At 24 months, 27.9%
LR-HPV genotypes b
Baseline, 48.0%
At 24 months, 39.4%
Any HPV genotypesb
Baseline, 0.99 (0.81-1.21)
At 24 months, 0.70 (0.53-0.91)
HR-HPV genotypes b
Baseline, 1.03 (0.79-1.33)
At 24 months, 0.65 (0.45-0.94)
LR-HPV genotypes b
Baseline, 0.99 (0.79-1.25)
At 24 months, 0.66 (0.49-0.91)
Serwadda et al., 2010 [59] Rakai district, uncircumcised HIV positive men aged 15-49 years; 103 men in intervention group and 107 men in control group Randomized controlled trial Roche HPV linear array At enrollment
HR-HPV genotypes a
Intervention group, 72.2%
Control group, 76.6%
LR-HPV genotypes a
Intervention group, 85.6%
Control group, 83.0%
At 24 months
HR-HPV genotypes a
Intervention; 55.3%
Control group; 71.7%
LR-HPV genotypes a
Intervention group, 49.4%
Control group, 77.4%
  At 24 months
RR for HR-HPV geno types 0.77 (0.62-0.97)
RR for multiple genotypes 0.53 (0.33-0.83)
Gray et al., 2010 [60] Rakai district, uncircumcised HIV negative men aged 15-49 years; 441 randomized to immediate circumcision (intervention) and 399 delayed circumcision (control) Randomized controlled trial Roche HPV linear array At enrollment
HR-HPV genotypes a
Intervention arm, 39.1%
Control arm, 38.6%
  
  1. HR* = High Risk
  2. LR** = Low Risk
  3. CI = Confidence Intervals
  4. a Denominator include all women tested
  5. b Denominator include only HPV positive women
  6. § Intervention refers to circumcision arm of the study
  7. §§ Control refers to non circumcision arm of the study